EGA Appoints Adrian van den Hoven as New Director General
The new director general has stepped into the European generic and biosimilar medicines industries at a challenging time when the trade association is facing numerous priority issues on the European agenda.
Adrian van den Hoven has been appointed as the new director general of the European Generic Medicines Association (EGA). The new director general is warmly welcomed by EGA’s president, Gudbjorg Edda Eggertsdottir, who commented in a press statement that Adrian van den Hoven’s expertise and proven track record of high level advocacy with European Institutions, large portfolio industries and other European stakeholders, will firmly drive forward EGA’s assignments.
Adrian van den Hoven will be working with EGA members to strengthen the generic and biosimilar medicines industries in Europe and to increase access to high quality medicines for patients at reasonable costs for member state healthcare budgets.
Adrian van den Hoven obtained his doctorate in political science from the University of Nice, France in 2000. He was previously deputy-director general of BUSINESSEUROPE, where his responsibilities included trade negotiations, bilateral relations as well as industrial, energy, environmental, and research policy in the International Relations and Industry Departments. He also has experience as an international relations researcher and an adjunct professor in Italy, France, and Canada.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
